Abstract No effective treatment for delayed radiationinduced neurotoxicity has been established. Its natural course is highly variable, but spontaneous recovery has been well documented. Here we report our experience with therapeutic anticoagulation in patients with cerebral lesions (n = 3), cranial nerve lesions (n = 1) or myelopathy (n = 4) attributed to irradiation. Two of three patients with cerebral lesions and the patient with cranial nerve lesions showed a minor improvement of clinical symptoms. In contrast, none of the patients with radiation myelopathy improved. No patient suffered hemorrhage or other adverse effects of anticoagulation. Overall, anticoagulation therapy demonstrates only modest activity for delayed radiationinduced neurotoxicity in this small case series.
Introduction
Potentially irreversible treatment-induced damage to the nervous system has become a relevant management problem as more cancer patients experience prolonged survival. Long-term radiation-induced neurotoxicity includes cerebral radionecrosis, diffuse cerebral white matter changes, radiation myelopathy, and plexus lesions [1] [2] [3] . There may be spontaneous recovery, but most clinical symptoms associated with radiation-induced neurotoxicity are slowly progressive. Treatment with steroids is often insufficiently effective and associated with significant side effects when administered for months. Since a vascular pathogenesis has been proposed to mediate some of these symptoms, anticoagulation using heparin and warfarin has been explored for possible efficacy [4, 5] . The largest series [5] reported some recovery of function in 5 of 8 patients with cerebral radionecrosis and all of 3 patients with myelopathy or plexopathy (1 myelopathy, 2 plexopathies). A further treatment option is hyperbaric oxygen therapy, based on the assumption that oxygen therapy induces neovascularization [6] [7] [8] . Finally, some patients with radiation-induced neurotoxicity may benefit from oral treatment with boswellic acid-containing medicines such as H15 [9] . Here we report our experience with anticoagulation using heparin or warfarin or both sequentially as an experimental treatment for delayed radiation-induced neurotoxicity.
Patients and methods
We searched the charts of the Department of Neurology from 1998 to 2007 for patients who received heparin or warfarin or both for the treatment of suspected radiationinduced injury to the nervous system. The diagnosis of radiation injury was based on clinical symptoms and signs that could not be attributed to progressive or recurrent tumor as defined by neuroimaging or to any other neurological disease. Moreover, a history of irradiation of the nervous system region affected was required. Eight patients were identified. Clinical histories, neuroimaging studies and the evolution of symptoms were reviewed.
Results
In 1998, it became practice at our institution to offer anticoagulation to patients with a tentative diagnosis of radiation-induced injury to the nervous system who had not responded to steroids and who had no contraindications for this treatment. Patient characteristics are summarized in the Table 1 . There were 3 patients with cerebral lesions, one patient with cranial nerve lesions, and 4 patients with radiation-induced myelopathy. None of the patients had a biopsy of the lesion before anticoagulation was started, but the neuroradiological features were not suggestive of recurrent tumor in any patient (Fig. 1a) . Neuroimaging findings were consistent with radiation injury (Fig. 2) . Spectroscopy performed in one patient supported the diagnosis of radiation-induced leukencephalopathy (Fig. 1b ). An unusual treatment predicted to induce radiation injury to the nervous system was only given to patient 2 who received two courses of WBRT for PCNSL. Six patients had also received chemotherapy before, during or after radiotherapy, which may have contributed to radiation injury of the nervous system. This is particularly true for patient 6 who had received multiple courses of intrathecal chemotherapy, too.
Patients 3, 4, 5, and 6 had had a prior course of steroids and had not responded. No patient was on steroids when anticoagulation was started. No patient was newly started on steroids when anticoagulation was instituted, excluding confounding effects of steroid comedication.
Two out of three patients with cerebral lesions (patients 2 and 3) and the patient with cranial nerve lesions (patient 4) showed a minor improvement of their clinical symptoms. These patients were switched from heparin to warfarin after a few days because the minor clinical response were seen early. Patient 1 refused to continue warfarin beyond day 2. In contrast, none of the patients with radiation myelopathy improved clinically, although patient 7 showed a distinct regression on MR imaging (Fig. 3) . Although this might be attributed to the anticoagulation therapy, it possibly occurred as a result of subsequent hyperbaric oxygen therapy or spontaneous recovery. Since the patient cohort reported earlier [5] included only one patient suffering radiationinduced myelopathy, the evaluation on the effects of anticoagulation on radionecrosis of the myelon is only preliminary.
Our patients 2 and 3 improved with regard to level of consciousness and hemiparesis within 3 days of the institution of anticoagulation, raising the possibility that anticoagulation was the cause for improvement. Partial remission of cranial nerve palsies took days in patient 4, rendering a causal relationship to anticoagulation more doubtful. The neurological deficits in the 4 patients with radiation myelopathy remained stable throughout the therapeutic trial of anticoagulation. No patient suffered hemorrhage or other adverse effects of anticoagulation therapy.
Discussion
The increasing use of more efficacious multimodality treatments for various types of cancer results in significant survival benefits for many patients, but has also raised awareness for therapy-related injury to the nervous system. Such lesions may often be multifactorial in origin and not only caused by irradiation, but also to chemotherapy, preexisting comorbidities, notably diabetes and cerebrovascular disease, as well as the underlying cancer itself. Although it is often difficult to distinguish radiation injury from recurrent tumor, such patients rarely undergo a biopsy for a histological verification of radiation injury to the nervous system. Steroids, anticoagulation [5] , hyperbaric oxygen [6] [7] [8] and boswellic acids [9] have been proposed to alleviate neurological deficits associated with delayed radiationinduced neurotoxicity. Given the relative rarity of this condition and the heterogeneity of patient characteristics, it is unlikely that prospective randomized trials may ever been performed to standardize management. Moreover, there may be distinct differences in the pathogenesis of various syndromes of radiation injury. Accordingly, specific syndromes may respond differentially to treatments such as steroids, anticoagulation or hyperbaric oxygen. Steroids are considered to be effective mainly for acute and subacute radiation-induced injury to the nervous system. No further studies on the possible beneficial role of anticoagulation have been published since 1994 [5] . The rationale of anticoagulation is based on histological observations of endothelial damage and lesions induced by irradiation [10] . The case series reported here is only the second in the literature to assess this treatment. Patients who responded clinically to i.v. heparin did so early and were then switched to warfarin. The only patient who experienced no benefit from warfarin discontinued warfarin anticoagulation after 2 days. Thus we feel that our observations justify a short trial of up to a week of anticoagulation with i.v. heparin in patients with presumptive radiation-induced cerebral lesions whereas the lack of any change in the symptoms and signs of all 4 . Axial T1w, contrast-enhanced T1w, and FLAIR images are presented from left to right. A star-shaped, hemorrhagic, contrastenhancing lesion (arrow) and a large edema (asterisk), consistent with a radiation injury, can be appreciated in the right parietal lobe patients with radiation-related myelopathy is not encouraging. Moreover, all reports on the apparent beneficial effects of therapeutic interventions for radiation-associated neurotoxicity must be considered with caution in view of the variable course of such lesions which includes spontaneous recovery. For instance, it is impossible to say whether the improvement seen in patient 7 (Fig. 3 ) was related to heparin or hyperbaric oxygen or reflected the natural course of the lesion.
More importantly, there is an increasing awareness of pseudoprogression of tumors within the CNS as an early misleading MRI feature after focal radiotherapy. This may lead to the erroneous assumption of treatment failure and trigger false therapeutic decisions [11, 12] . In summary, the present case series demonstrates that anticoagulation therapy is safe but has probably only modest activity in patients with delayed radiation-induced neurotoxicity. Prospective studies using stringent diagnostic criteria for therapy-induced Fig. 3 Fifty three year old man (patient 7) with multiple myeloma after spinal irradiation of Th 5-7 with 32 Gy. Sagittal, contrast-enhanced T1w (upper row), sagittal T2w (middle row), and axial T2w images (lower row) are shown. The first MRI showed a pronounced edema of the myelon at the level Th 5-9 and a significant contrast uptake (A, white arrows). Three months later, MRI showed regression with residual edema and reduced contrast uptake of the myelon at the level Th 5-6 (B, white arrows); 10 days of i.v. heparin therapy and 6 weeks of fraxiparine therapy as well as 40 administrations of hyperbaric oxygen had preceded the MRI. Follow-up 7 months after initial examination showed further improvement with only minimal residual findings (C, white arrows). Another 40 applications of hyperbaric oxygen had been administered injury to the nervous system are required to explore in more depth the therapeutic potential of both anticoagulants and hyperbaric oxygen therapy.
